22
Participants
Start Date
June 1, 2019
Primary Completion Date
February 15, 2022
Study Completion Date
February 16, 2022
Perampanel
Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
Placebo
Placebo given in place of perampanel during the pre-treatment period and lab session days.
Albert Arias, Richmond
University of Connecticut, Farmington
Yale New Haven Hospital Research Unit, New Haven
West Haven Veterans Affairs, West Haven
University of Connecticut
OTHER
Yale University
OTHER
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Virginia Commonwealth University
OTHER